Silicosis future or investigational therapies: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| (7 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Silicosis}} | {{Silicosis}} | ||
{{CMG}} | {{CMG}} {{AE}} {{AV}} | ||
==Overview== | ==Overview== | ||
Silicosis is an irreversible condition | Silicosis is an irreversible condition. Treatment options currently focus on alleviating the symptoms and preventing complications. | ||
==Future or Investigational Therapies== | ==Future or Investigational Therapies== | ||
Experimental treatments include | |||
===Systemic glucocorticoid therapy=== | |||
*In chronic silicosis with [[COPD]] flare up, [[prednisolone]] has been used and this resulted in statistically (although not clinically) significant improvements in [[lung volumes]], [[carbon monoxide|carbon monoxide diffusing capacity]], and [[partial pressure of arterial oxygen]]<ref name="pmid2008993">{{cite journal| author=Sharma SK, Pande JN, Verma K| title=Effect of prednisolone treatment in chronic silicosis. | journal=Am Rev Respir Dis | year= 1991 | volume= 143 | issue= 4 Pt 1 | pages= 814-21 | pmid=2008993 | doi=10.1164/ajrccm/143.4_Pt_1.814 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=2008993 }} </ref> | |||
===Tamoxifen citrate=== | |||
*[[Tamoxifen citrate]], a [[selective estrogen receptor modulator]] used for the treatment of [[breast cancer]] , inhibits the production of [[TGF-β|transforming growth factor-beta]] ([[TGF-β]]). TGF-β has important roles in the formation of [[fibrosis]] such as the modulation of inflammation, wound repair, and immunity by decreasing lymphocyte proliferation and encouraging growth of [[fibroblasts]]. Studies about the possible effects of [[tamoxifen]] on progression, prevention, and treatment of the fibrotic pulmonary silicosis disease considering the anti-fibrotic effect shown in aforementioned studies<ref name="pmid25218282">{{cite journal| author=Yoldas O, Karaca T, Bilgin BC, Yilmaz OH, Simsek GG, Alici IO et al.| title=Tamoxifen citrate: a glimmer of hope for silicosis. | journal=J Surg Res | year= 2015 | volume= 193 | issue= 1 | pages= 429-34 | pmid=25218282 | doi=10.1016/j.jss.2014.08.013 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25218282 }} </ref> | |||
===Whole-lung lavage=== | |||
*[[Bronchoalveolar lavage|Whole-lung lavage]] can be done based on the similarity of acute silicosis and [[pulmonary alveolar proteinosis]], although clinical utility is not very clear<ref name="pmid23632425">{{cite journal| author=Stafford M, Cappa A, Weyant M, Lara A, Ellis J, Weitzel NS et al.| title=Treatment of acute silicoproteinosis by whole-lung lavage. | journal=Semin Cardiothorac Vasc Anesth | year= 2013 | volume= 17 | issue= 2 | pages= 152-9 | pmid=23632425 | doi=10.1177/1089253213486524 | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=23632425 }} </ref> | |||
* Whole-lung | |||
==References== | ==References== | ||
Latest revision as of 13:41, 24 June 2015
|
Silicosis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Silicosis future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Silicosis future or investigational therapies |
|
Risk calculators and risk factors for Silicosis future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Overview
Silicosis is an irreversible condition. Treatment options currently focus on alleviating the symptoms and preventing complications.
Future or Investigational Therapies
Experimental treatments include
Systemic glucocorticoid therapy
- In chronic silicosis with COPD flare up, prednisolone has been used and this resulted in statistically (although not clinically) significant improvements in lung volumes, carbon monoxide diffusing capacity, and partial pressure of arterial oxygen[1]
Tamoxifen citrate
- Tamoxifen citrate, a selective estrogen receptor modulator used for the treatment of breast cancer , inhibits the production of transforming growth factor-beta (TGF-β). TGF-β has important roles in the formation of fibrosis such as the modulation of inflammation, wound repair, and immunity by decreasing lymphocyte proliferation and encouraging growth of fibroblasts. Studies about the possible effects of tamoxifen on progression, prevention, and treatment of the fibrotic pulmonary silicosis disease considering the anti-fibrotic effect shown in aforementioned studies[2]
Whole-lung lavage
- Whole-lung lavage can be done based on the similarity of acute silicosis and pulmonary alveolar proteinosis, although clinical utility is not very clear[3]
References
- ↑ Sharma SK, Pande JN, Verma K (1991). "Effect of prednisolone treatment in chronic silicosis". Am Rev Respir Dis. 143 (4 Pt 1): 814–21. doi:10.1164/ajrccm/143.4_Pt_1.814. PMID 2008993.
- ↑ Yoldas O, Karaca T, Bilgin BC, Yilmaz OH, Simsek GG, Alici IO; et al. (2015). "Tamoxifen citrate: a glimmer of hope for silicosis". J Surg Res. 193 (1): 429–34. doi:10.1016/j.jss.2014.08.013. PMID 25218282.
- ↑ Stafford M, Cappa A, Weyant M, Lara A, Ellis J, Weitzel NS; et al. (2013). "Treatment of acute silicoproteinosis by whole-lung lavage". Semin Cardiothorac Vasc Anesth. 17 (2): 152–9. doi:10.1177/1089253213486524. PMID 23632425.